NYSE:ZTSZoetis Competitors & Alternatives

Zoetis (NYSE:ZTS) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Volatility & Risk

Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Institutional & Insider Ownership

91.4% of Zoetis shares are owned by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.7%. Zoetis pays out 22.0% of its earnings in the form of a dividend. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Johnson & Johnson has raised its dividend for 24 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zoetis and Johnson & Johnson, as reported by MarketBeat.

Zoetis currently has a consensus price target of $149.00, suggesting a potential downside of 5.05%. Johnson & Johnson has a consensus price target of $164.2667, suggesting a potential upside of 11.77%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts clearly believe Johnson & Johnson is more favorable than Zoetis.

Profitability

This table compares Zoetis and Johnson & Johnson's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Zoetis and Johnson & Johnson's top-line revenue, earnings per share and valuation.

Johnson & Johnson has higher revenue and earnings than Zoetis. Johnson & Johnson is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Zoetis (NYSE:ZTS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Valuation and Earnings

This table compares Zoetis and Pfizer's top-line revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Zoetis. Pfizer is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Zoetis and Pfizer's net margins, return on equity and return on assets.

Dividends

Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.0%. Zoetis pays out 22.0% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Zoetis and Pfizer, as reported by MarketBeat.

Zoetis currently has a consensus price target of $149.00, suggesting a potential downside of 5.05%. Pfizer has a consensus price target of $38.8583, suggesting a potential upside of 2.83%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Zoetis.

Volatility & Risk

Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Institutional & Insider Ownership

91.4% of Zoetis shares are owned by institutional investors. Comparatively, 70.2% of Pfizer shares are owned by institutional investors. 0.2% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Zoetis beats Pfizer on 12 of the 17 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Valuation & Earnings

This table compares Merck & Co., Inc. and Zoetis' gross revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Merck & Co., Inc. and Zoetis' net margins, return on equity and return on assets.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.44 per share and has a dividend yield of 3.0%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Merck & Co., Inc. pays out 47.0% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a summary of recent ratings for Merck & Co., Inc. and Zoetis, as reported by MarketBeat.com.

Merck & Co., Inc. presently has a consensus target price of $94.9286, suggesting a potential upside of 17.33%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, research analysts plainly believe Merck & Co., Inc. is more favorable than Zoetis.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

74.3% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 91.4% of Zoetis shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Zoetis on 9 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Institutional & Insider Ownership

72.4% of AbbVie shares are held by institutional investors. Comparatively, 91.4% of Zoetis shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares AbbVie and Zoetis' gross revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and Zoetis' net margins, return on equity and return on assets.

Volatility and Risk

AbbVie has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for AbbVie and Zoetis, as reported by MarketBeat.com.

AbbVie presently has a consensus target price of $107.00, suggesting a potential upside of 15.46%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given AbbVie's stronger consensus rating and higher probable upside, research analysts plainly believe AbbVie is more favorable than Zoetis.

Dividends

AbbVie pays an annual dividend of $4.72 per share and has a dividend yield of 5.1%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. AbbVie pays out 52.8% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Summary

Zoetis beats AbbVie on 9 of the 17 factors compared between the two stocks.

Eli Lilly And Co (NYSE:LLY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Insider and Institutional Ownership

77.3% of Eli Lilly And Co shares are owned by institutional investors. Comparatively, 91.4% of Zoetis shares are owned by institutional investors. 0.1% of Eli Lilly And Co shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Eli Lilly And Co and Zoetis' gross revenue, earnings per share and valuation.

Eli Lilly And Co has higher revenue and earnings than Zoetis. Eli Lilly And Co is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eli Lilly And Co and Zoetis' net margins, return on equity and return on assets.

Risk & Volatility

Eli Lilly And Co has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Eli Lilly And Co and Zoetis, as reported by MarketBeat.com.

Eli Lilly And Co presently has a consensus target price of $169.7273, suggesting a potential upside of 12.68%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given Eli Lilly And Co's stronger consensus rating and higher probable upside, equities analysts clearly believe Eli Lilly And Co is more favorable than Zoetis.

Dividends

Eli Lilly And Co pays an annual dividend of $2.96 per share and has a dividend yield of 2.0%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Eli Lilly And Co pays out 49.0% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly And Co has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Summary

Eli Lilly And Co beats Zoetis on 8 of the 15 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Profitability

This table compares Bristol-Myers Squibb and Zoetis' net margins, return on equity and return on assets.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.80 per share and has a dividend yield of 2.9%. Zoetis pays an annual dividend of $0.80 per share and has a dividend yield of 0.5%. Bristol-Myers Squibb pays out 38.4% of its earnings in the form of a dividend. Zoetis pays out 22.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Analyst Ratings

This is a summary of recent recommendations and price targets for Bristol-Myers Squibb and Zoetis, as reported by MarketBeat.com.

Bristol-Myers Squibb presently has a consensus target price of $69.2857, suggesting a potential upside of 9.75%. Zoetis has a consensus target price of $149.00, suggesting a potential downside of 5.05%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, equities analysts clearly believe Bristol-Myers Squibb is more favorable than Zoetis.

Insider and Institutional Ownership

74.2% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 91.4% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Bristol-Myers Squibb has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Zoetis' gross revenue, earnings per share and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats Bristol-Myers Squibb on 10 of the 17 factors compared between the two stocks.